Technical Analysis for ACRX - AcelRx Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 1.96 -7.76% -0.17
ACRX closed down 7.76 percent on Tuesday, December 12, 2017, on 43 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical ACRX trend table...

Date Alert Name Type % Chg
Dec 12 Stochastic Reached Oversold Other 0.00%
Dec 12 Outside Day Range Expansion 0.00%
Dec 12 Wide Bands Range Expansion 0.00%
Dec 12 Oversold Stochastic Weakness 0.00%
Dec 11 Narrow Range Bar Range Contraction -7.76%
Dec 11 Wide Bands Range Expansion -7.76%
Dec 8 Wide Bands Range Expansion -6.67%
Dec 8 Oversold Stochastic Weakness -6.67%
Dec 7 180 Bearish Setup Bearish Swing Setup -8.84%
Dec 7 Narrow Range Bar Range Contraction -8.84%

Older signals for ACRX ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Basic chart:

AcelRx Pharmaceuticals, Inc., a development stage specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute and breakthrough pain. The company's principal product candidate is ARX-01, a Sufentanil NanoTab PCA system, which is in Phase III clinical trials for acute post-operative pain in patients in the hospital setting. Its product candidates also comprise ARX-02, a Sufentanil NanoTab BTP management system that has completed a Phase II clinical trial for the treatment of cancer patients who suffer from breakthrough pain; and ARX-03, a Sufentanil/Triazolam NanoTab, which has completed a Phase II clinical trial to provide mild sedation, anxiety reduction, and pain relief for patients undergoing painful procedures in a physician's office. In addition, the company's product candidate under development includes ARX-04, a Sufentanil Single-Dose NanoTab for the treatment of patients with moderate-to-severe acute pain either on the battlefield or in civilian settings of trauma or injury. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.
Is ACRX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 5.75
52 Week Low 1.55
Average Volume 2,009,176
200-Day Moving Average 2.7862
50-Day Moving Average 2.4754
20-Day Moving Average 2.1203
10-Day Moving Average 2.156
Average True Range 0.145
ADX 11.67
+DI 19.12
-DI 26.47
Chandelier Exit (Long, 3 ATRs ) 1.915
Chandelier Exit (Short, 3 ATRs ) 2.285
Upper Bollinger Band 2.3312
Lower Bollinger Band 1.9094
Percent B (%b) 0.12
BandWidth 19.893411
MACD Line -0.0542
MACD Signal Line -0.0672
MACD Histogram 0.013
Fundamentals Value
Market Cap 88.94 Million
Num Shares 45.4 Million
EPS -1.10
Price-to-Earnings (P/E) Ratio -1.78
Price-to-Sales 5.25
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.34
Resistance 3 (R3) 2.37 2.29 2.27
Resistance 2 (R2) 2.29 2.19 2.27 2.25
Resistance 1 (R1) 2.12 2.13 2.08 2.09 2.23
Pivot Point 2.04 2.04 2.02 2.02 2.04
Support 1 (S1) 1.87 1.94 1.83 1.84 1.69
Support 2 (S2) 1.79 1.88 1.77 1.67
Support 3 (S3) 1.62 1.79 1.65
Support 4 (S4) 1.59